KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Gsk (GSK) over the last 3 years, with Q4 2018 value amounting to $277.9 million.

  • Gsk's Current Deferred Revenue fell 1277.24% to $277.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $277.9 million, marking a year-over-year decrease of 1277.24%. This contributed to the annual value of $288.5 million for FY2018, which is 669.38% down from last year.
  • As of Q4 2018, Gsk's Current Deferred Revenue stood at $277.9 million, which was down 1277.24% from $318.6 million recorded in Q4 2017.
  • In the past 5 years, Gsk's Current Deferred Revenue registered a high of $318.6 million during Q4 2017, and its lowest value of $196.4 million during Q4 2016.
  • For the 3-year period, Gsk's Current Deferred Revenue averaged around $264.3 million, with its median value being $277.9 million (2018).
  • As far as peak fluctuations go, Gsk's Current Deferred Revenue skyrocketed by 6221.61% in 2017, and later crashed by 1277.24% in 2018.
  • Over the past 3 years, Gsk's Current Deferred Revenue (Quarter) stood at $196.4 million in 2016, then skyrocketed by 62.22% to $318.6 million in 2017, then dropped by 12.77% to $277.9 million in 2018.
  • Its last three reported values are $277.9 million in Q4 2018, $318.6 million for Q4 2017, and $196.4 million during Q4 2016.